Teva Pharmaceutical Industries Ltd.'s results from a Phase II/III study ARM-TD (Aim to Reduce Movement in Tardive Dyskinesia) have been published in Neurology, the American Academy of Neurology's medical journal. Read More »
CVs Health has earned #50 in the ranking for DiversityInc's 2017 Top 50 Companies for Diversity. This is the first time that CVS has been on the list, though it was #25 on the Noteworthy listing in the past. Read More »
Novo Nordisk announced this month a new combo therapy for the treatment of diabetes. Read More »
The American Society of Health-System Pharmacists has awarded 11 pharmacy students with both recognition and a cash reward for their excellence in their education, both on campus and pharmacy practice. Read More »
Imprimis Pharmaceutical Inc. launch its new Simple drops glaucoma drops at the American Society of Cataract and Refractive Surgery 2017 meeting at the Los Angeles Convention Center this month. Read More »
Teva Pharmaceutical Industries Ltd. will make a generic version of Vytorin (ezetimibe and simvastatin) available in America. Read More »
EMD Serono has received Food and Drug Administration approval of BAVENCIO (avelumab) as a treatment for locally advanced or metastatic urothelial carcinoma. Read More »
Genentech's Phase III IMvigor211 clinical trial did not meet its primary endpoint of overall survival. Read More »
CVS Health is offering Hepatitis A vaccinations in Oahu following an import of frozen raw tuna that was positive for containing the virus. Read More »
GSK has made a $139 million investment in a biopharmaceutical manufacturing site in Rockville, Maryland. Read More »
Eight real-world analyses regarding Entyvio (vedolizumab) for treating adults with moderate to severe ulcerative colitis and Crohn's disease were presented at the 2017 Digestive Disease Week annual scientific meeting. Read More »
Waismann Method Medical Group directors have warned of a new naloxone-resistant drug hitting the streets, calling for an awareness program for acrylfentanyl and warning of a serious public health emergency. Read More »
The Food and Drug Administration has approved Genentech's Lucentis as a treatment for all forms of diabetic retinopathy, the leading cause of blindness among working age adults in the country. Read More »
The first new drug approved specifically to treat amyotrophic lateral sclerosis (ALS), commonly referred to a Lou Gehrig’s Disease, in over two decades was approved in less than a year, thanks in large part to the FDA working in conjunction with Mitsubishi Tanabe Pharma Corp. and the ALS Association. Read More »
Allegra drug developer Sanofi supports Bike to Work Day, a day where Americans are urged to ride bicycles to work instead of driving. Read More »
A patent application has been filed for a new cannabinoid-based topical therapy that will treat glaucoma, the second-leading cause of blindness. Read More »
Valeant Pharmaceuticals Inc. and EyeGate Pharmaceuticals have entered an exclusive, global licensing agreement. Read More »
The Academy of Managed Care Pharmacy's members are urging Congress and President Donald Trump's administration to include comprehensive pharmacy benefits in any health care reform bill they attempt to pass. Read More »
Advanced Pharma Inc., which does business as Avella of Houston, is voluntarily recalling unexpired sterile injectable products labeled "latex free" that were produced at the company’s Houston location between Sep. 1, 2016 and Feb. 16, 2017. Read More »
The U.S. Food and Drug Administration has approved Siliq (brodalumab) as a treatment for adults with moderate-to-severe plaque psoriasis. Read More »
Alerts Sign-up
